Discounted Cash Flow (DCF) Analysis Levered

ASLAN Pharmaceuticals Limited (ASLN)

$ 1.505
+0.01 (+0.33%)

Free Cash Flow

Year
A/P
2016
Actual
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 11.49---------
Revenue (%)
Operating Cash Flow -5.57---------
Operating Cash Flow (%)
Capital Expenditure -0.45---------
Capital Expenditure (%)
Free Cash Flow -6.02---------

Weighted Average Cost Of Capital

Share price $ 1.505
Beta 2.389
Diluted Shares Outstanding 38.45
Cost of Debt
Tax Rate 4.56
After-tax Cost of Debt 6.27%
Risk-Free Rate
Market Risk Premium
Cost of Equity 12.766
Total Debt 18.97
Total Equity 57.86
Total Capital 76.83
Debt Weighting 24.69
Equity Weighting 75.31
Wacc

Build Up Free Cash Flow

Year
A/P
2016
Actual
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 11.49---------
Operating Cash Flow -5.57---------
Capital Expenditure -0.45---------
Free Cash Flow -6.02---------
WACC
PV LFCF ---------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 11.16
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 4.65
Equity Value -
Shares Outstanding 38.45
Equity Value Per Share -